Overview
- The review in Microbiology and Molecular Biology Reviews reports increasing virulence and a global footprint reaching at least 61 countries.
- CDC data cited in coverage show roughly 7,000 U.S. infections across 27 states this year.
- Conventional tests frequently misidentify the yeast, delaying treatment and hindering infection control in healthcare facilities.
- Multidrug resistance is rising, with documented pan‑resistant strains that defeat all four major antifungal classes.
- Countermeasures highlighted include three late‑stage antifungal candidates, the FDA-approved rezafungin for invasive Candida, and ongoing vaccine research.